We thank Dr Main for his valuable comments regarding the use of antidepressants as analgesics. As Dr Main has correctly mentioned, most of the clinical trails on the effectiveness of duloxetine in chronic pain management were performed by the manufacturers of duloxetine, which is a funding bias. Lunn, Hughes and Wiffen have concluded that there is moderate-quality evidence in managing pain in diabetic peripheral neuropathy with a dose of 60 mg and 120 mg of duloxetine.8